Latest Intellectual Property News

International Graphite Limited (IG6) has partnered with Italian chemical giant ALKEEMIA to establish a cutting-edge graphite processing facility in Italy, targeting production by late 2027. This joint venture aims to secure Europe's graphite supply chain amid rising demand and regulatory pressures.

GCM Corporation has completed the full transfer of its proprietary Very High Density (VHD) technology, gaining exclusive global ownership with payments tied to future revenue milestones.

Eve Health Group is advancing its proprietary reformulation platform with two fast-onset products launched under Australia's SAS-B pathway, targeting large underserved markets in women's and men's health. The company’s capital-light, partner-led model aims for rapid revenue growth post-ARTG registration.

Synertec Corporation Limited has reported a robust first half of FY26, with a 20% increase in group revenue and a significant $135 million engineering tender pipeline, underscoring its growing footprint in energy technology and engineering services.

Recce Pharmaceuticals has expanded its intellectual property footprint with a newly granted patent in Brazil, protecting its innovative synthetic anti-infectives against a broad range of infections. This milestone strengthens Recce’s position in one of South America’s largest antibiotic markets.

BlinkLab’s smartphone-based Dx1 autism screening technology has been selected for Morocco’s government-funded national early screening program, marking a major milestone in digital health adoption and autism care.

Energy Technologies Limited, via its subsidiary Cogenic, has acquired Maradin Ltd’s laser optical engineering IP portfolio, positioning itself at the forefront of laser projection technology for AR, VR, and defence applications.

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

AdAlta Limited has been granted a key Canadian patent for its anti-fibrotic drug AD-214, completing its composition of matter protection across all major commercial markets. This milestone strengthens the company’s intellectual property portfolio and underpins its commercial strategy for AD-214.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.